Walgreens partners with Boehringer Ingelheim on clinical trials for obesity treatment

Walgreens Boots Alliance has landed another partnership to recruit participants for research as it continues to expand its clinical trials business.

The pharmacy retail giant has announced that it will partner with German pharmaceutical company Boehringer Ingelheim to leverage select Walgreens community pharmacies as clinical trial sites for people who are overweight, living with obesity, and who have type 2 diabetes.

The aim of the partnership is to improve access and address equitable health representation in clinical trials, especially among Black and Hispanic adults, the companies said. 

Additionally, Boehringer is partnering with EmVenio Research to complement the initiative by introducing mobile research units to extend reach and provide additional options for participation.

Walgreens first launched its clinical trial business in June 2022, a step at the time towards growing its health care efforts. The company has since signed more than 35 clinical trial contracts with drugmakers.